Search for content, post, videos

First patient dosed in Oncopeptides’ study

Jakob Lindberg

Oncopeptides announces today that the first patient has been dosed in the pivotal phase III study OCEAN.

The study is targeting Late-Stage Relapsed Refractory (RRMM) patients with Multiple Myeloma. It is designed as a head-to-head comparative study where the result will show whether Ygalo is more effective, just as effective, or less effective than the current standard of care treatment option pomalidomide for late-stage RRMM patients.

“We are of the firm belief that Ygalo will help late-stage multiple myeloma patients both in terms of efficacy and tolerability. These patients have a poor prognosis and a significant medical need for more and better treatment options. We are pleased to announce that the first patient in our pivotal phase III study OCEAN has been dosed. This is a milestone for Ygalo and for us as a company, and takes us one step closer to making Ygalo available for late-stage multiple myeloma patients.” said Jakob Lindberg, CEO of Oncopeptides.